Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden.
advanced Parkinson’s disease
caregiver burden
intestinal infusion
levodopa/carbidopa
quality of life; QoL
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
04
2020
accepted:
01
10
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
The aim of this study was to assess the burden and the quality of life (QoL) perceived by caregivers assisting advanced Parkinson's disease (PD) patients. Consecutive advanced PD patients treated with levodopa/carbidopa intestinal gel (LCIG) or continuous subcutaneous apomorphine infusion (CSAI) or care as usual (CU) and their care partners were recruited during routine visits according to a cross-sectional design. Caregiver's distress was assessed by Zarit Burden Interview (ZBI) and a QoL survey to evaluate and understand the burden experienced by care partners during family and working activities. A total of 126 patients (53 LCIG, 19 CSAI and 54 CU) and their care partners were enrolled. The ZBI score boxplot showed that LCIG and CU populations have a similar distribution (ZBI inter-quartile range [IQR] values respectively 18-42 for LCIG and 19-43 for CU group), while the CSAI group has a wider score range (IQR 16-52). Caregivers assisting patients in treatment with LCIG have more time to perform family or household duties (p=0.0022), or to engage in leisure activities (p=0.0073) compared to CU, while no difference was found when compared to CSAI group. Approximately 50% of the care partners showed mood changes in the last 6 months and LCIG and CSAI had less impact on caregiver's mood compared to CU. Patients treated with LCIG were more independent in taking a bath or shower without assistance and were more able to move and walk without assistance. Care partners of advanced PD patients treated with device-aided therapies have more time for their own life and a better perception of their QoL with a tendency to an improvement of mood compared with those of patients treated with CU.
Identifiants
pubmed: 33293815
doi: 10.2147/NDT.S256217
pii: 256217
pmc: PMC7719333
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2899-2912Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Modugno et al.
Déclaration de conflit d'intérêts
N. Modugno reports fees for oral presentations from AbbVie, UCB, Zambon and Bial. A. Antonini has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, AbbVie, Zambon, Bial, Ever Pharma, Neuroderm, Therevance, Biogen; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - PD_Pal Grant 825,785, Ministry of Education University and Research (MIUR) Grant ARS01_01081. He serves as consultant for Boehringer–Ingelheim for legal cases on pathological gambling”. A. Tessitore declares speaking honoraria and travel expenses for attending meetings from AbbVie. P. Marano declares consultancy fees from AbbVie. F.E. Pontieri received honoraria for speaker activity from Zambon, AbbVie, Bial, compensation for serving in the Steering Committee of an international grant from AbbVie; he also received an unconditioned grant for research activity from Zambon. N. Tambasco received speaker honoraria from Lundbeck and AbbVie. M. Canesi declares grants from UCB, Zambon and Ralpharma. G. Fabbrini received payment for International Congress from Zambon; he is also the editorial board for Parkinsonism and Related Disorders. R. Quatrale has received honoraria for consulting services and symposia from AbbVie and Zambon. P. Solla has received honoraria for participation in advisory boards from AbbVie. G. Gualberti, G. Melzi, are employees of AbbVie Italy and may own AbbVie stocks/options. The other authors report no conflicts of interest in this work.
Références
J Geriatr Psychiatry Neurol. 2018 Nov;31(6):319-328
pubmed: 30244631
Parkinsonism Relat Disord. 2015 Jun;21(6):629-34
pubmed: 25892660
Neurologia. 2018 Apr;33(3):154-159
pubmed: 27443241
Rev Med Chil. 2013 Mar;141(3):320-6
pubmed: 23900322
J Am Med Dir Assoc. 2016 Jul 1;17(7):626-32
pubmed: 27143237
Parkinsonism Relat Disord. 2019 Feb;59:65-73
pubmed: 30852149
J Neurol. 1998 May;245 Suppl 1:S39-41
pubmed: 9617723
J Parkinsons Dis. 2014;4(3):517-21
pubmed: 24903924
NPJ Parkinsons Dis. 2018 Apr 17;4:12
pubmed: 29675463
J Mov Disord. 2015 Jan;8(1):26-32
pubmed: 25614783
J Gerontol B Psychol Sci Soc Sci. 2003 Mar;58(2):P112-28
pubmed: 12646594
J Neurol. 1998 May;245 Suppl 1:S10-4
pubmed: 9617716
J Neurol. 2018 Sep;265(9):2005-2014
pubmed: 29951701
J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135
pubmed: 30006821
Rehabil Res Pract. 2014;2014:718527
pubmed: 25298895
Acta Neurol Scand. 2015 Apr;131(4):203-10
pubmed: 25212106
J Neurol. 2015 Feb;262(2):337-45
pubmed: 25381461
J Geriatr Psychiatry Neurol. 2017 Sep;30(5):235-252
pubmed: 28743212
Parkinsonism Relat Disord. 2015 Jan;21(1):1-11
pubmed: 25457815
J Neuropsychiatry Clin Neurosci. 2012 Fall;24(4):478-83
pubmed: 23224455
Int Psychogeriatr. 2011 Jun;23(5):797-805
pubmed: 21205379
Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):221-30
pubmed: 22458623
Mov Disord. 2007 May 15;22(7):924-31; quiz 1060
pubmed: 17238193
Parkinsonism Relat Disord. 2006 Jan;12(1):35-41
pubmed: 16271496
Eur J Phys Rehabil Med. 2008 Mar;44(1):39-45
pubmed: 18385627
Rev Neurol (Paris). 2018 Dec;174(10):711-715
pubmed: 30032927
J Neurol. 2018 May;265(5):1124-1137
pubmed: 29516169
J Geriatr Psychiatry Neurol. 2012 Dec;25(4):208-14
pubmed: 23172765
Neurol Sci. 2018 May;39(5):835-839
pubmed: 29445989
Front Aging Neurosci. 2018 Apr 24;10:120
pubmed: 29740312
Heart. 2004 May;90(5):518-22
pubmed: 15084548
Parkinsonism Relat Disord. 2017 May;38:90-92
pubmed: 28238650